Last reviewed · How we verify
NCT04985071: PF
Complication of Pancreatic Fistula and Bleeding After Pancreaticoduodenectomy in Treatment Periampullary Cancer
trial testing Pancreaticoduodenectomy in Periampullary Cancer in 183 participants. Completed in 31 October 2023.
31 October 2023
Quick facts
| Lead sponsor | Vo Truong Quoc |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 183 |
| Start date | 1 August 2021 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 October 2023 |
| Sites | 1 location across Vietnam |
Drugs / interventions tested
- Pancreaticoduodenectomy
Conditions studied
- Periampullary Cancer — all drugs for Periampullary Cancer →
- Pancreatic Fistula — all drugs for Pancreatic Fistula →
- Bleeding — all drugs for Bleeding →
Sponsor
Vo Truong Quoc
Who can join
Adults 18 to 85, any sex, with Periampullary Cancer or Pancreatic Fistula. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multi-site study will be done across Hepatobiliary and Pancreatic Surgery Department at Cho Ray Hospital and University and Pharmacy Center. Patients who are diagnosed with periampullary cancer from August 2021 to August 2023 will be underwent pancreaticoduodenectomy. We will follow-up for their pancreatic fistula and bleeding complication and analysis some risk factors.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04985071
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pancreaticoduodenectomy
Trials testing the same drug.
- NCT06132087 — PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemothe · NA · active not recruiting
- NCT07159672 — Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy · completed
- NCT05389917 — Three-Dimensional Vascular Reconstruction of the Pancreas on Multidetector Computed Tomography Images and Its Impact on · unknown
- NCT05017207 — Clinically Relevant Pancreatic Fistula After Pancreaticoduodenectomy · completed
- NCT04596865 — Recurrence After Whipple's (RAW) Study · completed
Other recruiting trials for Periampullary Cancer
Currently open trials in the same condition.
- NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
- NCT07155525 — Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas · Phase 3 · recruiting
- NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting
- NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
- NCT07022015 — Predictive Risk Factors for Pancreatic Fistula After Pancreaticoduodenectomy · NA · recruiting
Other Vo Truong Quoc trials
Trials by the same sponsor.
- NCT05017207 — Clinically Relevant Pancreatic Fistula After Pancreaticoduodenectomy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04985071 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vo Truong Quoc
- Last refreshed: 13 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04985071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing